<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40491">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579252</url>
  </required_header>
  <id_info>
    <org_study_id>AC-AD-003</org_study_id>
    <secondary_id>2015-000630-30</secondary_id>
    <nct_id>NCT02579252</nct_id>
  </id_info>
  <brief_title>24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease</brief_title>
  <acronym>ADAMANT</acronym>
  <official_title>A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axon Neuroscience SE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axon Neuroscience SE</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of AADvac1 in the treatment of patients with
      mild Alzheimer's disease.

      60% of participants will receive AADvac1 and 40% of participants will receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease (AD) is a chronic progressive neurodegenerative disorder of the brain.
      Over the course of the disease, pathological proteins accumulate in the brain, damaging
      neurons, thus causing them to lose their connections and die.

      Currently available treatments are designed to compensate for the neurotransmitter loss
      caused by the disease without affecting the disease process itself.

      AADvac1 is designed to raise antibodies against pathological tau protein (the primary
      constituent of neurofibrillary pathology in AD). These antibodies are expected to prevent
      tau protein from aggregating, to facilitate the removal of tau protein aggregates and
      prevent the spreading of pathology, slowing or halting the progress of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (all-case treatment-emergent adverse events except local reactions)</measure>
    <time_frame>24 months</time_frame>
    <description>The safety and tolerability of AADvac1 in the treatment of patients with mild Alzheimer disease, as assessed by AEs, vital signs, ECG, laboratory measures, MRI of the brain, physical and neurological examination, Columbia Suicide Severity Rating Scale (C-SSRS) and review of the Patient Diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating (CDR) Sum of Boxes</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Custom cognitive battery (composite standard score)</measure>
    <time_frame>24 months</time_frame>
    <description>A composite standard score will be calculated from the following tests:
Cogstate International Shopping List Task (memory)
immediate free recall
delayed free recall
delayed recognition
Cogstate One Card Learning Task (memory)
Cogstate One Card Back Task (memory)
Category Fluency Test (executive function, language)
Letter Fluency Test (executive function, language)
Digit Symbol Coding (executive functioning, working memory and processing speed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living questionnaire (version for Mild Cognitive Impairment) (ADCS MCI ADL)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory: Fludeoxyglucose Positron Emission Tomography (FDG PET) assessment of brain metabolism (change in cerebral glucose metabolic rate expressed as Standardised Uptake Value Ratio [SUVR] change, multiple regions of interest)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: MRI volumetry</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Cerebrospinal fluid (CSF) biomarkers</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>AADvac1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AADvac1 is a suspension for subcutaneous injection. AADvac1 is provided in single-use vials. Dosage: 40 µg Axon peptide 108 (coupled to keyhole limpet haemocyanin (KLH)) using aluminium hydroxide (containing 0.5 mg Al3+) as adjuvant, in a phosphate buffer.
Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is a suspension for subcutaneous injection. Placebo is provided in single-use vials. Dosage: aluminium hydroxide (containing 0.5 mg Al3+), in a phosphate buffer. Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AADvac1</intervention_name>
    <arm_group_label>AADvac1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (abbreviated):

          -  Diagnosis of probable Alzheimer's disease according to the revised National Institute
             on Aging-Alzheimer's Association (NIA-AA) criteria (McKhann 2011).

          -  Mini Mental State Examination (MMSE) score ≥ 20 and ≤ 26.

          -  Brain MRI finding consistent with the diagnosis of Alzheimer's disease

          -  Medial temporal lobe atrophy: Scheltens score of ≥ 2 (on a scale of 0-4 on the more
             atrophied side) AND/OR positive AD biomarker profile in the CSF (amyloid+, tau+)

          -  At least 6 years of formal elementary education.

          -  Age 50-85 years.

          -  Fluency in the local language and sufficient auditory and visual capacities to allow
             neuropsychological testing.

          -  Ability to read and understand the informed consent.

          -  Stable therapy with an acetylcholinesterase inhibitor for at least 3 months prior to
             screening.

          -  If the patient is on memantine treatment, the dose regimen must be stable for at
             least 3 months prior to screening.

          -  Hachinski Ischemia Scale score ≤ 4.

          -  Availability of a caregiver.

          -  Female patients must be either surgically sterile or at least 2 years postmenopausal.

          -  Male patients must either be surgically sterile, or he and his female spouse/partner
             who is of childbearing potential must be using highly effective contraception
             starting at screening and continuing throughout the study period.

          -  Patient provides written informed consent.

        Exclusion criteria (abbreviated):

          -  Participation in another clinical study within 3 months prior to screening.

          -  Pregnant or breastfeeding female.

          -  Not expected to complete the clinical study.

          -  Known allergy to components of the vaccine.

          -  Contraindication for MRI imaging.

          -  Any of the following detected by brain MRI:

               -  Infarction in the territory of large vessels

               -  More than one lacunar infarct.

               -  Any lacunar infarct in a strategically important location.

               -  Confluent hemispheric deep white matter lesions (Fazekas grade 3).

               -  Other focal lesions which may be responsible for the cognitive status of the
                  patient or any other abnormalities associated with significant central nervous
                  disease other than Alzheimer's disease.

          -  Surgery (under general anaesthesia) within 3 months prior to screening and/or
             scheduled surgery (under general anaesthesia) during the whole study period.

          -  Patient has a history and/or currently suffers from a clinically significant
             autoimmune disease, or is expected to receive immunosuppressive or immunomodulatory
             treatment at the present or in the future.

          -  Recent history of cancer (last specific treatment ≤ 5 years prior to Screening).

          -  Myocardial infarction within 2 years prior to screening.

          -  Hepatitis B, C, HIV or Syphilis.

          -  Active infectious disease.

          -  Presence and/or history of immunodeficiency.

          -  Patient currently suffering from a clinically important systemic illness:

               -  poorly controlled congestive heart failure (NYHA ≥ 3)

               -  BMI &gt; 40

               -  poorly controlled diabetes (HbA1c &gt; 7.5%)

               -  severe renal insufficiency (eGFR &lt; 30 mL/min)

               -  chronic liver disease - ALT (alanine aminotransferase) &gt; 66 U/L in females or &gt;
                  80 U/L in males, AST (aspartate aminotransferase) &gt; 82 U/L

               -  QTc interval prolongation in ECG (&gt; 450 ms)

               -  other clinically significant systemic illness, if considered relevant by the
                  investigator

          -  Hypothyroidism, defined as TSH (thyroid-stimulating hormone) elevation &gt; 5.000
             mcIU/mL, and/or FT4 levels &lt; 0.7 ng/dL. Patients with corrected hypothyroidism are
             eligible for the study provided that treatment has been stable for 3 months before
             study entry.

          -  Valid diagnosis of a significant psychiatric illness such as schizophrenia, any type
             of psychotic disorder or bipolar affective disorder.

          -  Current depressive episode (Geriatric Depression Scale GDS ≥ 6) or major depressive
             episode within the last 1 years.

          -  Metabolic or toxic encephalopathy or dementia due to a general medical condition.

          -  History of alcohol or drug abuse or dependence within the past 2 years.

          -  Wernicke's encephalopathy.

          -  History or evidence of any CNS disorder other than AD that could be the cause of
             dementia.

          -  Cerebrovascular disease (ischemic or haemorrhagic stroke), or diagnosis of possible,
             probable or definite vascular dementia.

          -  Epilepsy.

          -  Treatment with experimental immunotherapeutics including intravenous immunoglobulin
             within 3 months prior to screening.

          -  Treatment with experimental therapies for AD aiming at disease-modification within 3
             months prior to screening.

          -  Patient is currently being treated or was treated in the past with any active
             vaccines for AD.

          -  Treatment with immunosuppressive drugs.

          -  Change in dose of previous and current medications within the last 30 days prior to
             Screening (V01), if considered clinically relevant by the investigator.

          -  Vitamin B12 deficiency (serum vitamin B12 &lt; 191 pg/mL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reinhold Schmidt, Prof. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University, Graz, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matej Ondrus, MD</last_name>
    <phone>00421 220 921 620</phone>
    <email>ondrus@axon-neuroscience.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petr Novak, MD, PhD</last_name>
    <phone>00421 220 921 620</phone>
    <email>petr.novak@axon-neuroscience.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ordination Dr. Bancher</name>
      <address>
        <city>Horn</city>
        <state>Niederosterreich</state>
        <zip>3580</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Bancher, MD.Univ.Doz.</last_name>
      <phone>﻿﻿+43298226614200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Neurologie</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhold Schmidt, Prof.</last_name>
      <phone>+43 (0)316/385-12981</phone>
      <email>reinhold.schmidt@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Reinhold Schmidt, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abteilung Psychiatrie und Psychotherapie, LKH Hall</name>
      <address>
        <city>Hall in Tirol</city>
        <state>Tirol</state>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Marksteiner, UnivProf.Dr.</last_name>
      <phone>﻿﻿+435050433000</phone>
      <email>josef.marksteiner@tilak.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Innsbruck</name>
      <address>
        <city>Inssbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imrich Blasko, MD</last_name>
      <phone>﻿﻿+4351250481608</phone>
      <email>imrich.blasko@i-med.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne, Mezinarodni centrum klinickeho vyzkumu (ICRC), Centrum pro kognitivni poruchy, Neuro 2</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katerina Sheardova, MD, PhD</last_name>
      <phone>﻿﻿+420603198029</phone>
      <email>ksheardova@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove, Neurologicka Klinika</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Valis, MD, PhD</last_name>
      <phone>﻿﻿+420495835233</phone>
      <email>valismar@seznam.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodni ustav dusevniho zdravi (NÚDZ), Department of cognitive disorders - AD Center</name>
      <address>
        <city>Klecany</city>
        <zip>250 67</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ales Bartos, Doc,MD,PhD</last_name>
      <phone>﻿﻿+420283088160</phone>
      <email>ales.bartos@nudz.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha</city>
        <zip>128 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Rusina, MD</last_name>
      <phone>﻿﻿+420604236997</phone>
      <email>robert.rusina@lf1.cuni.cz</email>
    </contact>
    <investigator>
      <last_name>Evzen Ruzicka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jakub Hort, Prof,MD,PhD,</last_name>
      <phone>﻿﻿+420603265166</phone>
      <email>jakub.hort@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Klinik für Psychiatrie und Psychotherapie, Modul Altersmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Haas</last_name>
      <phone>﻿﻿+4930450517688</phone>
      <email>brigitte.haas@charite.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Peters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf, Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Wesser</last_name>
      <phone>﻿﻿+4940741024009</phone>
      <email>i.wesser@uke.uni-hamburg.de</email>
    </contact>
    <investigator>
      <last_name>Holger Jahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln, Klinik für Psychatrie</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Engels</last_name>
      <phone>﻿﻿+4922147832888</phone>
      <email>tanja.engels@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Frank Jessen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität Heidelberg, Zentralinstitut für Seelische Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Dünkel</last_name>
      <phone>﻿﻿+4962117033317</phone>
      <email>tanja.duenkel@zi-mannheim.de</email>
    </contact>
    <investigator>
      <last_name>Lutz Frölich, Prof.MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München, Klinik und Poliklinik fur Psychiatrie und Psychotherapie</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Schels</last_name>
      <phone>﻿﻿+498941400</phone>
      <email>Friederike.Schels@mri.tum.de</email>
    </contact>
    <investigator>
      <last_name>Timo Grimmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Klaus Christian Steinwachs</name>
      <address>
        <city>Nürnberg</city>
        <zip>90402</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Wilfried Mück, MD</last_name>
      <phone>﻿﻿+49911222885</phone>
      <email>dr.mueck@t-online.de</email>
    </contact>
    <investigator>
      <last_name>Klaus-Christian Steinwachs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Schuster, MD</last_name>
      <phone>﻿﻿+4973150063000</phone>
      <email>joachim.schuster@uni-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Markus Otto, Prof.MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej KENDRON</name>
      <address>
        <city>Bialystok</city>
        <zip>15-420</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Wilkiel, RN</last_name>
      <phone>﻿﻿+48504589869</phone>
      <email>mwilkiel@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Jan Kochanowicz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Podlaskie Centrum Psychogeriatrii</name>
      <address>
        <city>Bialystok</city>
        <zip>15-756</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Maslowska, BSc</last_name>
      <phone>﻿﻿+48856610298</phone>
      <email>magdamaslowska111@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jacek Dobryniewski, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pallmed prowadzacy NZOZ Dom Sue Ryder w Bydgoszczy Centrum Psychoneurologii Wieku Podeszlego</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Megger</last_name>
      <phone>﻿﻿+48523485642</phone>
      <email>m.megger@domsueryder.org.pl</email>
    </contact>
    <investigator>
      <last_name>Robert Kucharski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wielospecjalistyczna Poradnia Lekarska Synapsis</name>
      <address>
        <city>Katowice</city>
        <zip>40-123</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Smilowski, MD, PhD</last_name>
      <phone>﻿﻿+48322583061</phone>
      <email>marek.smilowski2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lech Szczechowski, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Care Clinic</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janusz Krzestek</last_name>
      <phone>﻿﻿+48609527827</phone>
      <email>poczta@careclinic.katowice.pl</email>
    </contact>
    <investigator>
      <last_name>Maciej Matuszczyk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Neurologii Klinicznej, Krakowska Akademia Neurologii</name>
      <address>
        <city>Kraków</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Golosz, BSc, MSc</last_name>
      <phone>﻿﻿+48124269280</phone>
      <email>marta.golosz@neurologia.org.pl</email>
    </contact>
    <investigator>
      <last_name>Andrzej Szczudlik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Sp. z o.o.</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Kulka, MD</last_name>
      <phone>﻿﻿+48814402474</phone>
      <email>malgorzata.kulka@komed-ck.pl</email>
    </contact>
    <investigator>
      <last_name>Roman Chwedorowicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niepubliczny ZOZ Senior</name>
      <address>
        <city>Sopot</city>
        <zip>81-855</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magdalena Szafirowska</last_name>
      <phone>﻿﻿+48509647806</phone>
      <email>mszafirowska@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dorota Ussorowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EUROMEDIS Sp. z o.o.</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolina Sorbian</last_name>
      <phone>﻿﻿+48918136322</phone>
      <email>karolina.sorbian@euromedis.pl</email>
    </contact>
    <investigator>
      <last_name>Marcin Ratajczak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne NeuroProtect</name>
      <address>
        <city>Warszawa</city>
        <zip>﻿01-697</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Biel-Czarnecka</last_name>
      <phone>﻿﻿+48606965833</phone>
      <email>Marta.biel@neuroprotect.pl</email>
    </contact>
    <investigator>
      <last_name>Maciej Czarnecki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr.Carol Davila Emergency University Central Military Hospital, Psychiatry Clinic</name>
      <address>
        <city>Bucharest</city>
        <zip>﻿010816</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Grigorescu</last_name>
      <phone>﻿﻿+40722630235</phone>
      <email>gggrig@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Vasile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Psihomedical Consult SRL</name>
      <address>
        <city>Bucharest</city>
        <zip>﻿010816</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxana Dinu</last_name>
      <phone>﻿﻿+40722762805</phone>
      <email>roxana.niculescu2007@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Catalina Tudose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Dr. Constantin Gorgos&quot; Psychiatry Hospital Titan</name>
      <address>
        <city>Bucharest</city>
        <zip>﻿030447</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Today</last_name>
      <phone>﻿﻿+40723808540</phone>
      <email>elainetod@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Maria Sandulescu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cluj-Napoca Emergency Clinical County Hospital</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400012</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bogdan Nemes</last_name>
      <phone>﻿﻿+40751684894</phone>
      <email>nemes.bogdan@umfcluj.ro</email>
    </contact>
    <investigator>
      <last_name>Horia Coman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurologicka Ambulancia s.r.o.</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>974 04</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Dupejova, MD</last_name>
      <phone>﻿﻿+421903636272</phone>
      <email>dupejova@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurologicka ambulancia</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>974 04</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Dupejova, MD</last_name>
      <phone>00421903636272</phone>
      <email>dupejova@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nestatna psychiatricka ambulancia</name>
      <address>
        <city>Bratislava</city>
        <zip>81107</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Janikova, MD</last_name>
      <phone>﻿﻿+421905885719</phone>
      <email>eva-j@ba.psg.sk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto, I. Neurologicka klinika LF UK a UNB</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Turcani, Prof,MD,PhD</last_name>
      <phone>﻿﻿+421905106957</phone>
      <email>peter.turcani@sm.unb.sk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava, Psychiatricka klinika LFUK a UNB</name>
      <address>
        <city>Bratislava</city>
        <zip>81369</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Zlnayova, MD</last_name>
      <phone>﻿﻿+421907184903</phone>
      <email>zlnayova@email.cz</email>
    </contact>
    <investigator>
      <last_name>Maria Kralova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica L Pasteura Kosice, Psychiatricka klinika</name>
      <address>
        <city>Kosice</city>
        <zip>﻿041 90</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Vancikova, MD</last_name>
      <phone>﻿﻿+421903313242</phone>
      <email>janav1@outlook.sk</email>
    </contact>
    <investigator>
      <last_name>Slavka Dubinska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEURES, s.r.o. Neurologicka ambulancia</name>
      <address>
        <city>Krompachy</city>
        <zip>﻿05342</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juraj Smik</last_name>
      <phone>﻿﻿+421908327472</phone>
      <email>jurajsmik66@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Renata Smikova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum zdravia R.B.K., s.r.o., Psychiatricka ambulancia</name>
      <address>
        <city>Svidnik</city>
        <zip>﻿089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Keselicova</last_name>
      <phone>﻿﻿+421918702477</phone>
      <email>svetlana.keselicova@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Rastislav Korba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pro Mente Sana S.R.O., Psychiatricka Ambulancia</name>
      <address>
        <city>Trencin</city>
        <zip>91108</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Branislav Motovsky</last_name>
      <phone>﻿﻿+421327440972</phone>
      <email>branislav.motovsky@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Hastova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou Zilina, Psychiatricke oddelenie</name>
      <address>
        <city>Zilina</city>
        <zip>﻿012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Hanzelova, MD</last_name>
      <phone>﻿+421415689593</phone>
      <email>martina1hanzelova@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univerzitetni klinični Center Ljubljana, Neurology Clinic</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milica Gregoric Kramberger</last_name>
      <phone>﻿﻿+38615222311</phone>
      <email>milica.kramberger@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Milica Gregoric Kramberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre Maribor</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marija Menih</last_name>
      <phone>﻿﻿+3863212364</phone>
      <email>marija.menih@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Martin Rakuša</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus Malmö, Minneskliniken</name>
      <address>
        <city>Malmö</city>
        <zip>SE-20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pia Frejd Pålsson</last_name>
      <phone>﻿﻿+4640335629</phone>
      <email>Pia.FrejdPalsson@skane.se</email>
    </contact>
    <investigator>
      <last_name>Henrik Östlund</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset, Minnesmottagningen</name>
      <address>
        <city>Mölndal</city>
        <zip>SE-43141</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jonsson</last_name>
      <phone>﻿﻿+46313438668</phone>
      <email>Michael.jonsson@neuro.gu.se</email>
    </contact>
    <investigator>
      <last_name>Anne Börjesson-Hanson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malin Aspö</last_name>
      <phone>﻿﻿+46858585275</phone>
      <email>malin.aspo@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Niels Andreasen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset I Uppsala, Minnes-och geriatrikmottagningen</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva-Lis Lundberg</last_name>
      <phone>﻿﻿+46186117229</phone>
      <email>eva-lis.lundberg@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Lena Kilander, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Kontsekova E, Zilka N, Kovacech B, Skrabana R, Novak M. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. Alzheimers Res Ther. 2014 Aug 1;6(4):45. doi: 10.1186/alzrt277. eCollection 2014.</citation>
    <PMID>25478018</PMID>
  </reference>
  <reference>
    <citation>Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther. 2014 Aug 1;6(4):44. doi: 10.1186/alzrt278. eCollection 2014.</citation>
    <PMID>25478017</PMID>
  </reference>
  <reference>
    <citation>Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, Vince-Kazmerova Z, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, Brunner M, Staffen W, Rainer M, Ondrus M, Ropele S, Smisek M, Sivak R, Winblad B, Novak M. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017 Feb;16(2):123-134. doi: 10.1016/S1474-4422(16)30331-3. Epub 2016 Dec 10.</citation>
    <PMID>27955995</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>October 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>tau protein</keyword>
  <keyword>active</keyword>
  <keyword>immunization</keyword>
  <keyword>KLH</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>tau</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
